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 ABSTRACT 
Introduction 
Oncoplastic breast surgery is used to extend the role of breast-conserving surgery (BCS) to 
women with an unfavourable tumour to breast volume ratio. However, large-breasted women 
with a relatively small breast cancer may be offered bilateral reduction mammoplasty (BRM) 
despite being suitable for standard BCS as the more complex surgery may have advantages in 
terms of patient satisfaction and reduced adverse effects of radiotherapy.  
Patient and methods 
This retrospective study evaluated surgical and patient-related outcome measures (PROMs) 
in large-breasted women with early (<3cm) breast cancer, who have undergone unilateral 
standard BCS or BRM. 
Results 
This series included 157 women, 87 in the unilateral BCS group and 70 in the BRM group. 
Median age was 60.2 years (range: 33-83.9). Median follow-up was 36 months (range: 9.8-
76). Tumour size, rates of axillary dissection, adjuvant chemotherapy and tumour bed 
irradiation boost were significantly greater in the BRM group (p<0.05). The surgical 
complication rate was not significantly different (43.7%vs.34.3%, p=0.253). Re-excision 
rates were higher in the standard BCS group (p<0.05). Time to chemotherapy was similar, 
but time to radiotherapy was longer after BRM surgery (p=0.025). Despite worse prognostic 
factors, more complex surgery and more aggressive adjuvant treatment, patients report better 
satisfaction and physical functioning and fewer adverse effects of radiotherapy after BRM 
than standard unilateral BCS. This difference was not statistically different in this small study 
(p>0.05).  
Conclusion 
Limitations of this study mean it can only be regarded as hypothesis-generating. Nonetheless, 
the trends merit a prospective study to investigate the optimal management of smaller breast 
cancers in larger-breasted women.  
 
 INTRODUCTION 
Oncoplastic breast-conserving surgery is used in the developed world for the treatment of 
early breast cancer, however practice is not currently standardised[1] as oncoplastic 
guidelines have tended to focus on breast reconstruction[2]. Not all patients with breast 
cancer are suitable for or require oncoplastic BCS. The usual indication for a reduction 
mammoplasty (level II oncoplastic approach) is an unfavourable tumour to breast volume 
ratio or a challenging tumour location, or both, such that a poor cosmetic result might be 
expected after standard BCS[3,4].  Previous studies have demonstrated that standard and 
oncoplastic BCS are equivalent in terms of loco-regional control[5,6] Large-breasted women 
with a relatively small breast cancer may be offered the choice between standard BCS (i.e. 
wide local excision / lumpectomy) and oncoplastic BCS. In these cases of favourable tumour 
to breast volume ratio a standard wide local excision is the simplest surgical solution but 
larger breast size and ptosis are associated with worse cosmetic outcome after BCS and 
radiotherapy, with an increased rate of asymmetry, fibrosis, retraction and late radiation 
changes[7-10]. Radiation dose distribution is heterogeneous in larger breasts, and therefore a 
reduction mammoplasty, while surgically more complex, may lead to improved dose 
distribution, a reduction in the adverse effects of radiotherapy, and better long term 
symmetry, cosmesis and patient satisfaction[3,11-14]. Modern Intensity Modulated 
Radiotherapy (IMRT) reduces the inhomogeneity, but does not eliminate the effect of “large-
breastedness” on cosmetic outcome [10]. The risk of subsequent new primary breast cancer is 
reduced by the extent of breast tissue excised[15,16] thus there is a concomitant advantage in 
this respect. Furthermore, women may benefit from a bilateral reduction mammoplasty in 
terms of quality of life, independent of their cancer treatment [17-19]. Long-lasting benefits 
of reduction mammoplasty are said to include reduction in neck, shoulder, back and breast 
pain, together with improvement in body posture, sleep, choice of clothing, sexual 
relationships and ability to work[20,21]. 
Conversely, bilateral reduction mammoplasty (BRM) could be considered overtreatment for a 
unilateral tumour; it is a longer procedure and carries the risk of complications in both breasts 
which may delay adjuvant treatment.[1,3,22]. 
At our institution bilateral reduction mammoplasty is offered to, and often sought by, suitable 
patients as an alternative to standard BCS. All patients considering bilateral reduction 
mammoplasty for smaller tumours are counselled about the specific complications and 
potential benefits of both this procedure and the simpler alternative, unilateral standard BCS, 
hence patient preference plays a large part in decision-making.  
The aim of this study was to evaluate surgical outcomes and patient satisfaction in two 
cohorts of larger -breasted women who underwent either standard BCS or bilateral reduction 
mammoplasty for a unilateral breast cancer smaller than 3 cm on pre-operative imaging. We 
chose this cut-off assuming that a tumour of such size could be removed with clear margins 
from a large breast using standard BCS.  
PATIENTS AND METHODS 
Institutional Service Evaluation approval was obtained to study the outcome of patients 
undergoing BRM between June 2009 and November 2014. Eligible patients were sent the 
BCT Module of the BREAST-Q questionnaire by post and no reminder was sent to patients 
who did not reply. The comparison cohort of patients who underwent unilateral BCS are a 
subset of patients involved in an on-going study of outcomes after BCS, for which ethical 
approval was obtained. The study involved medical photography and completion of the 
BREAST-Q questionnaire face-to-face at the time of their annual visit for surveillance 
mammography between 1 and 6 years post-operatively [23]. The subset of patients with 
larger breasts were identified as women with an estimated bra cup size ≥ D on 2D photos and 
breast volume >500cm3 on 3D surface imaging of the healthy breast using the VECTRA XT 
System (Canfield Scientific). 
Patients who did not undergo radiotherapy, or who had bilateral or multi-centric cancer were 
excluded. Patients who went on to have a mastectomy for involved margins, developed 
distant disease or were lost to follow-up were excluded from the evaluation of patient 
satisfaction. 
Data including patient demographics, clinico-pathological details, surgical outcomes and 
BREAST-Q scores were collected from a prospectively maintained database and recorded in 
a Microsoft Excel spreadsheet (Microsoft Corp, Redmond, Wash.). 
Surgical outcome measures included complications within 30 days of surgery according to 
the Clavien-Dindo Classification[24]. We only considered complications occurring in the 
breast, excluding axillary events. Grade 1 complications include minor deviations from the 
normal postoperative course without the need for any treatment (eg seroma/haematoma not 
requiring drainage, minor skin necrosis, delayed wound healing). Grade 2 complications 
include patients requiring pharmacological treatment (eg antibiotics for wound infection). 
Grade 3 complications are divided into 3a, if an intervention under local anaesthesia is 
required (eg seroma/haematoma which were drained under ultrasound guidance, skin necrosis 
requiring debridement), or 3b, if general anaesthesia is needed (i.e. major skin necrosis, 
wound infection requiring debridement, postoperative bleeding). Margin involvement (at the 
time of this study) was considered negative if greater than 1mm from invasive cancer and 
2mm from DCIS). Margin re-excision, length of hospital stay, re-admission within 30 days 
and delay (>6 weeks) in starting adjuvant treatment were also recorded. 
Patient-reported outcomewas evaluated postoperatively using a validated questionnaire 
(BREAST-Q BCT Module) for both cohorts[25]. A score for each of the nine domains within 
the questionnaire was derived and then transformed on a scale of 0-100 according to the 
BREAST-Q protocol with higher scores equating to higher satisfaction.  
The mean and standard deviation were calculated for all parametrically distributed variables, 
whilst the median and the range were calculated for non-parametric ones. Fisher’s exact test 
was applied for categorical data, Student’s t-test for continuous data and the Mann-Whitney 
test for non-parametric data. A p value of <0.05 was considered statistically significant.  
RESULTS 
In total 157 larger-breasted women were evaluated, 87 in the unilateral BCS cohort and 70 in 
the bilateral cohort. The median age of patients at the time of surgery was 60.2 years (range: 
33-83.9), with a median BMI of 29.6 kg/m2 (range: 20.3-46.3). The median follow-up was 36 
months (range: 9.8-76). The two cohorts were compared for demographics and clinico-
pathological characteristics (Table 1). There were no significant differences in terms of 
patient features, except for the age, which was significantly higher in the unilateral group 
(p=0.0001). The median breast volume of the unilateral breast cohort was 758,47cm3 (range: 
303,9-1407,3). The tumour size was significantly higher in the bilateral group both on 
preoperative imaging and postoperative histological analysis (p=0.001, p=0.001) and the 
central location was more frequent in the bilateral reduction group (p=0.004), indeed, 16 
patients underwent nipple-areola complex excision. The excised volume from the index 
breast was significantly greater in the bilateral group (p<0.001). In the bilateral group the 
rates of axillary dissection, adjuvant chemotherapy therapy and additional radiation boost to 
the tumour bed were significantly greater than in the unilateral group (p=0.002, p=0.0001, 
p=0.04, p=0.0001 respectively). 
The surgical outcomes are reported in Table 2. The complication rate was 43.7% (38 patients) 
in the unilateral group and 34.3% (24 patients) in the bilateral groups, this was not 
statistically significant (p =0.253) (Table 2).  The median length of hospital stay was 
statistically significantly longer in the bilateral cohort being 1 night (range: 0-6) compared 
with 0 (range: 0-4) in the unilateral group (p<0.001). The unplanned re-admission rate was 
not significantly higher in the bilateral group (2 versus 1, p value=0.587). Unplanned return 
to theatre was more frequent after bilateral surgery, while the rate of re-excision of margins 
was higher after unilateral surgery. Neither of these differences was statistically significant (p 
values: 0.087 and 0.138). Regarding the time from index surgery to starting first adjuvant 
treatment, thirteen patients started chemotherapy greater than 6 weeks after primary surgery, 
4 being unilateral and 9 bilateral cases (p=0.336), the most common reason being patient’s 
choice, to accommodate pre-arranged holidays etc. A grade 1 complication delayed the start 
of adjuvant chemotherapy in only two patients, one in each group. Median time to starting 
radiotherapy was longer after bilateral surgery. This was statistically significant though not 
oncologically relevant (57 versus 53 days, p=0.025). Index surgery was taken as the starting 
point because patients undergoing complex bilateral surgery may experience delays owing to 
complications while those undergoing standard BCS may experience delays as a result of re-
excision. 
Patient reported outcome measures 
The response rate for the unilateral cohort, completing the BREAST-Q within a prospective 
study, was 100%. The response rate for patients in the bilateral cohort who were sent the 
questionnaire by post was 55.2% (32 patients out of 58 who were sent the questionnaire). 
BREAST-Q scores are reported in Table 3. There was no statistical difference in patient-
reported outcomeafter unilateral standard BCS or bilateral reduction mammoplasty for any 
domain (p>0.05) though there was a trend towards better satisfaction with the breast, less 
concern about adverse effects of radiotherapy and better physical wellbeing. 
DISCUSSION 
Although oncoplastic breast surgery was initially offered to extend the indications for BCS, 
there are some women for whom both oncoplastic techniques and standard wide local 
excision are options. This study set out to evaluate surgical outcomes and patient satisfaction 
in the specific subset of larger-breasted women with a relatively small breast cancer, who 
were suitable for either wide local excision or therapeutic mammoplasty with immediate 
contralateral symmetrisation. 
Therapeutic mammoplasty is the application of breast reduction and mastopexy techniques to 
treat breast cancer and represents only one option in the wide spectrum of oncoplastic 
procedures available. Depending on breast and tumour size it often results in asymmetry and 
necessitates a bilateral procedure. MacMillan et al. divided the ideal candidates for 
therapeutic mammoplasty into three categories:  
1) women who see breast conservation in the form of therapeutic mammoplasty as a 
preferable alternative to mastectomy and reconstruction. 
2) women who need or desire a breast reduction and 
3) women with ptotic breasts who are accepting of an altered breast shape but do not 
necessarily wish to be significantly smaller[26] 
 
However these indications raise the issue of which procedure is the correct gold standard 
against which to compare results. Many suggest that as therapeutic mammoplasty is 
predominantly used to extend the role of breast conservation to those who would otherwise 
require mastectomy, and as the tumour pathology more closely matches a mastectomy cohort, 
this should be the comparator[27].  Yet in many series including our own[6], there are a 
number of women with smaller tumours or ptotic breasts i.e. the latter two indications, for 
whom standard BCS is an option. These should be analysed separately, and in comparison 
with standard BCS. In order to analyse this scenario, we included larger-breasted women who 
were suitable for breast reduction and had a tumour smaller than 3 cm so were also suitable 
for standard BCS. Previous literature about oncoplastic surgery in comparison to BCS 
highlighted the benefits of the former in cases of unfavourable tumour-breast volume ratio, 
when wider margins or better aesthetic results were achievable[1,3]. There are currently no 
published comparative studies of surgical, oncological and patient-reported outcome in the 
scenario of favourable tumour–breast volume ratio, when the choice for therapeutic 
mammoplasty is mainly patient-driven.  
In our study we identified women with larger breasts and tumours up to 3 cm who opted for 
either bilateral reduction mammoplasty or standard BCS. Women who underwent standard 
BCS were older than those who chose bilateral reduction mammoplasty (table 1), perhaps 
because younger women were more accepting of bilateral surgery and more likely to desire 
breast reduction. Regarding tumour characteristics, the bilateral cohort had more aggressive 
disease, reflected in larger tumour size and higher rates of axillary dissection, adjuvant 
treatment and boost radiation and, as expected, greater excised volume. As the groups were 
not well matched for patient and tumour characteristics, oncological outcomes were not 
evaluated. Margin involvement and hence re-excision were significantly more frequent in the 
unilateral cohort (p values: 0.02, 0.007), but no meaningful conclusions can be drawn 
because the women who ultimately converted to mastectomy had been excluded from this 
retrospective study.  
We found no significant difference between the two cohorts in terms of total complication 
rate (p value: 0.253) or specific grade of complication (p value>0.05) (Table 2). However 
there were differences in the specific types of grade 1 complications, mainly seromas (n=11) 
in the unilateral group and delayed wound healing (n=15) in the bilateral group. These may 
be very different in impact on patients, for example, delaying the start of adjuvant 
radiotherapy. Grade 2 complications were mostly represented by infections in both groups 
and grade 3 by ultrasound-guided aspiration of seroma/haematoma. There is a trend towards a 
higher rate of grade 3b complications (requiring intervention under general anaesthesia) in 
the bilateral group, which is reasonable as the surgical technique of breast reduction yields a 
higher risk of specific complications (e.g. nipple necrosis, flap necrosis, haematoma) 
requiring further surgery. 
Although the length of hospital stay is one night longer in the bilateral group as expected 
from more complex surgery, the difference is mitigated by the lower rate of readmission for 
re-excision of margins. Previous studies of oncoplastic surgery showed that it did not delay 
any adjuvant treatment[28,29], but our results confirm this finding for chemotherapy only. 
Our cohorts did not differ significantly in the median time interval from surgery to 
chemotherapy (p = 0.825), but the median time to radiotherapy is significantly longer in the 
bilateral cohort (p = 0.002). As this difference is 53 versus 57 days, it is unlikely to be 
oncologically relevant. Furthermore almost 30% of the complications were on the 
symmetrising side which would not affect the timing of radiotherapy.  
The strength of this study is the evaluation of PROMs using the BREAST-Q questionnaire. 
The breast-conserving therapy module is the most recent module to be introduced and this is 
the first report of its use to compare standard BCS with oncoplastic BCS. Despite the 
difference in surgery, the two cohorts’ scores were not statistically significant in any domain. 
The power of our study is limited by the smaller numbers responding to the questionnaire in 
the bilateral reduction cohort. When planning PROMs studies, thought should be given to the 
mode of distribution. The bilateral cohort was sent questionnaires in the post once, no 
reminder was sent in case of no response, to respect the patient’s choice. This could have led 
to bias, but the lower quartile was 57 in both cohorts, suggesting that unsatisfied women did 
participate in both studies. The overall response rate was 55.2% and 81.3% of these 
completed the psychosexual domain. Conversely, the unilateral group participated as part of a 
prospective study and met an investigator face-to-face23. The completion rate was 100%, but 
paradoxically only 62.1% completed the psychosexual domain. This raises the possibility that 
response rates, and possibly answers, are different according to the context in which patients 
complete the questionnaire. We are now also examining the option of online completion of 
PROMs questionnaires by patients (ePROMs). 
Notwithstanding bilateral surgery, larger tumour size and more adjuvant treatment the 
bilateral cohort showed a clear trend towards higher patient satisfaction (80 versus 68) and 
less concern about adverse effects of irradiation (100 versus 89). There is also a more subtle 
trend towards better physical well-being (perhaps owing to reduction of back / neck pain) in 
the bilateral group, and worse psychological well-being (possibly linked to the worse 
prognosis of their disease). All of these hypotheses should be tested on a larger and better-
matched prospective sample. Median values for other domains are too close to draw any 
conclusion. The heterogeneity of methods of evaluation of patient satisfaction in the literature 
makes it difficult to compare our results with previously published studies which have 
suggested better satisfaction after therapeutic mammoplasty compared to standard 
BCS[30,31]. One limitation of this study is that we only assessed postoperative patient 
satisfaction, and pre-existing dissatisfaction could impact post-operative satisfaction. For 
example, wide local excision aims to maintain the same breast shape as before surgery, but if 
a larger-breasted patient had poor body image pre-operatively, she would be dissatisfied after 
surgery as well. Conversely, dissatisfaction with breasts is likely to be a factor swaying a 
larger-breasted woman with a favourable tumour-breast volume ratio towards more complex 
surgery in the form of bilateral reduction mammoplasty and the change in size and the shape 
of breasts as a result of surgery is likely to lead to greater satisfaction with the outcome.  
  
CONCLUSION 
This cohort study demonstrated that larger-breasted women with favourable tumour to breast 
volume ratio have similar complication rates and achieve high levels of satisfaction after both 
standard breast conserving surgery and bilateral reduction mammoplasty. Despite not 
reaching statistical significance, these data are hypothesis-generating for future prospective 
studies with larger and better-matched cohorts and health economic evaluation which could 
eventually provide clear evidence of advantages and disadvantages of therapeutic 
mammoplasty compared with standard BCS. 
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Table 1 Patient demographics and clinico-pathological characteristics 
 Unilateral  
n(%) or  
median (IQR) 
 
Bilateral 
n (%) or  
median (IQR) 
 
p value 
Total 87 70  
Mean age ± SD, (years) 63.3±9.1 56.1±9.0 0.0001 
BMI (kg/m2) 30(27-33) 29.3(25.2-32.5) 0.584 
Median follow-up (months) 36(22-49) 36.5(22.3-51) 0.357 
Smoking history (ex or current) 40(46.0) 34(48.6) 0.75 
Ethnicity 
White 
Other 
76(87.4) 
11(12.6) 
56(80) 
14(20) 
0.278 
0.278 
Location of tumour 
Central 
Upper Outer 
Upper Inner 
Lower Outer 
Lower Inner 
4(4.6) 
46(52.9) 
17(19.5) 
12(13.8) 
8(9.2) 
14(20) 
30(42.9) 
8(11.4) 
13(18.6) 
5(7.1) 
0.004 
0.148 
0.191 
0.512 
0.774 
Neo-adjuvant chemotherapy 8(9.2) 14(20) 0.065 
Median preoperative tumour  size (mm) 
T1a 
T1b 
T1c 
T2 
15(10.5-23) 
1(1.2) 
21(24.1) 
40(46) 
25(28.7) 
22(16.25-27) 
5(7.1) 
5(7.1) 
21(30) 
39(55.8) 
0.001 
0.09 
0.005 
0.008 
0.001 
 
Median histological tumour size (mm) 
pT1a 
pT1b 
pT1c 
pT2 
 
20(14-28) 
4(4.6) 
10(11.5) 
37(42.5) 
36(41.4) 
 
28(17-40) 
3(4.3) 
4(5.7) 
16(22.9) 
47(67.1) 
 
0.001 
1 
0.26 
0.11 
0.001 
 
Specimen weight (g) 42(29-59.5) 250(124.75-453) <0.001 
Axillary dissection 
Sentinel Lymph Node Biopsy 
No axillary treatment 
10(11.5) 
67(77.0) 
10(11.5) 
23(32.9) 
45(64.3) 
2(2.9) 
0.002 
0.110 
0.067 
Pathology 
IDC 
IDC+DCIS 
ILC 
DCIS 
other 
12(13.8) 
53(60.9) 
8(9.2) 
10(11.5) 
4(4.6) 
17(24.3) 
37(52.9) 
6(8.6) 
4(5.7) 
6(8.6) 
0.102 
0.334 
1 
0.265 
0.343 
ER+ 
 PR+ 
Her2+ 
76(87.4) 
66(75.9) 
6(6.9) 
58(82.9) 
54(77.1) 
9(12.9) 
0.499 
1 
0.276 
Patients with positive axillary nodes (macro-metastases) 17(19.5) 23(32.9) 0.0002 
Adjuvant Treatment 
Chemotherapy 
Endocrine Therapy 
Radiation Boost 
15(17.2) 
71(81.6) 
16(18.4) 
31(44.3) 
56(80) 
36(51.4) 
0.001 
0.84 
0.0001 
 
Table 2 Surgical outcomes 
Complications 
Unilateral Cohort 
n=87 (%) 
Bilateral Cohort 
n=70 (%) 
p value 
grade 1 
grade 2 
grade 3a 
grade 3b 
24(28) 
17(20) 
4(5) 
0 
20(29) 
6(9) 
1(1) 
3(4) 
1 
0.069 
0.382 
0.087 
Number of patients with a complication 38 (44)  24 (34) 0.253 
Length of hospital stay in nights 0(0-0.5) 1(1-2) <0.001 
Readmissions for complications 
Return to theatre for complications 
Margin involvement 
Return to theatre for margin re-excision 
1(1) 
0 
14(16) 
14(16) 
2(3) 
3(4) 
3(4) 
2(3) 
0.587 
0.087 
0.02 
0.003 
Time to chemotherapy (days) 
Time to radiotherapy (days) 
40 (36-50) 
53 (46-63) 
39 (33-48) 
57 (53-71) 
0.551 
0.025 
 
 
Table 3 Patient satisfaction: BREAST-Q median score and interquartile range 
BREAST-Q Unilateral Cohort (n=87) Bilateral Cohort (n=32) P value No answer (%) 
Satisfaction with the breast 68(57-82.5) 80(57-95.5) 0.320 0 
Adverse effects of RT 89(80-100) 100(80-100) 0.099 1(0.8) 
Psychosocial  well-being 82(69-100) 76(63-100) 0.705 0 
Sexual well-being 57(49.5-69) 46(36-58) 0.079 39(26.9) 
Physical well-being 75(67-92) 81(70.5-92) 0.422 2(1.4) 
Satisfaction with Information 75(65.5-100) 84(72-100) 0.153 3(2.1) 
Satisfaction with Surgeon 100(98-100) 100(96-100) 0.595 3(2.1) 
Satisfaction with Team 100(100-100) 100(100-100) 0.287 0 
Satisfaction with Office 100(100-100) 100(96.5-100) 0.245 0 
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